Literature DB >> 30714458

Allergy accelerates the disease progression of chronic rhinosinusitis.

Keng-Chung Shen1, Yi-Tsen Lin1,2, Chih-Feng Lin1, Chin-Hao Chang3, Te-Huei Yeh1.   

Abstract

BACKGROUND: The role of allergy in the development of chronic rhinosinusitis (CRS) in East Asians is not clear. AIMS/
OBJECTIVES: The aim was to investigate the impact of allergies in the clinical characteristics of chronic rhinosinusitis.
MATERIAL AND METHODS: A total of 138 CRS patients who underwent endoscopic sinus surgery were included. A brief history of rhinosinusitis symptoms, blood eosinophil count, blood-specific allergen tests, computed tomography (CT) scan findings, Lund-Mackay (LM) CT scores, and Sino-Nasal Outcome Test (SNOT-22) Questionnaire scores, and sinoscopy findings at 3 and 6 months postoperatively.
RESULTS: The ImmunoCAP test was positive in 71(51%) patients and negative in 67(49%) patients. The mean age of those who received endoscopic sinus surgery was 7-years younger in the allergic group compared with the non-allergic group (p = .008). The peripheral eosinophil count in the allergic group was higher than that of the non-allergic group (p = .008). The LM scores and SNOT-22 scores were not significantly different between the two groups. The recurrence rate of nasal polyps in the allergic group was higher but without statistical significance. CONCLUSIONS AND SIGNIFICANCE: Allergy may accelerate the disease progression of CRS. The presence of the serum-specific IgE was correlated with peripheral eosinophil percentage, especially in the CRSwNP patients.

Entities:  

Keywords:  Allergy; Lund-Mackay score; SNOT-22; chronic rhinosinusitis; eosinophil

Mesh:

Year:  2019        PMID: 30714458     DOI: 10.1080/00016489.2018.1552368

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  Effect of Xinyi Biyan Pill in Adjuvant Treatment of Patients with Chronic Rhinosinusitis and Its Influence on Serum Inflammatory Factors and Immune Function.

Authors:  Qingfu Bao; Yu Zhou; Lei Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-27       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.